Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JNJ

2 Stocks That Are More Than COVID-19 Plays

While the COVID-19 pandemic benefitted Johnson & Johnson (JNJ) and Pfizer (PFE) significantly as their vaccines helped the world recover from the crisis, these stocks are more than just COVID-19 plays because of their strong product portfolio and pipeline. They are well-positioned to capitalize on the rising chronic diseases, an…

StockNews.com

This Is What Whales Are Betting On Johnson & Johnson

Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Better Buy: Axsome Therapeutics vs. Johnson & Johnson

Axsome Therapeutics (AXSM) and Johnson & Johnson (JNJ) are expected to benefit from the rising number of chronic diseases and continued technological advancements in the pharmaceutical sector. But which of these stocks is a better buy now? Read more to find out….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson Whale Trades For August 23

Benzinga

3 Stocks to Help You Grow the Nest Egg

The S&P 500 and the Nasdaq closed the last week lower, ending the four-week winning streak on concerns over the hawkish Fed and weak economic data of some of the influential countries. However, investors should consider fundamentally sound growth stocks The Kroger (KR), Johnson & Johnson (JNJ), and Taiwan Semiconductor…

StockNews.com

2 Pharma Stocks That'll Make You Rich in the Long Term

Substantial investments in R&D, an aging population, and growing demand for advanced drugs to treat chronic diseases should drive the pharmaceutical industry’s growth. Therefore, investing in fundamentally strong and dividend-paying pharma stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) could help dodge the current market volatility and generate substantial…

StockNews.com

2 Stocks to Buy While Their Prices Are Down

Amid persistent market uncertainties due to rising inflation and a potential recession, we believe fundamentally sound, beaten-down stocks Johnson & Johnson (JNJ) and Costco Wholesale (COST) could gain solid momentum in the near term and could be wise investments now. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Large-Cap Healthcare Stocks to Buy for Bigger Gains

Due to the inelastic demand and rising investments, the healthcare sector is witnessing investor confidence amid these uncertain market conditions. Although persistent macroeconomic headwinds might affect stocks in this space, investors could consider buying dividend-paying large-cap stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and UnitedHealth Group (UNH) to…

StockNews.com

Johnson & Johnson Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

3 Dividend-Paying Stocks to Consider During a Recession

Rising inflation, the Fed’s hawkish stance to tame it, and an economic contraction for two consecutive quarters have stoked fears of a recession in the U.S. economy. Amid the likely economic downturn, investors could consider investing in stocks that provide a steady income in the form of dividends. Therefore, we…

StockNews.com

2 Warren Buffet Stocks You'll Wish You Bought Sooner

Warren Buffett’s long-term value investing strategy serves as a guide for several investors amid uncertain market conditions. Thus, we think it could be wise to scoop up shares of fundamentally sound Warren Buffett holdings, The Procter & Gamble (PG), and Johnson (JNJ). Continue Reading….

StockNews.com

Johnson & Johnson Whale Trades For July 25

Benzinga

Things Looking Up at Johnson & Johnson?

Johnson & Johnson (NYSE: JNJ) released their financial report for the second quarter of 2022, this week, demonstrating strong growth and promising guidance for the rest of the year. Analysts seem to agree, as the consensus rating for JNJ is MODERATE BUY.

Benzinga

Looking At Johnson & Johnson's Recent Whale Trades

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

4 Outperforming Stocks for People Who Hate Volatility

The stock market has been experiencing immense volatility lately as investors remain concerned over the multi-decade high inflation and the Fed’s aggressive interest rates to control it. However, fundamentally sound stocks Johnson & Johnson (JNJ), Coca-Cola FEMSA (KOF), KT Corporation (KT), and Weis Markets (WMK) are outperforming the broader market.…

StockNews.com

Here's Why Every Investor Might Want to Buy Shares of JNJ

Including dividends, Johnson & Johnson (JNJ) has delivered exceptional returns over the past decade. Given the company’s robust financials, strong dividend-paying history, solid growth prospects, and higher-than-industry profitability, the stock could be an excellent investment amid the current uncertain market conditions. Read on….

Benzinga

Looking At Johnson & Johnson's Recent Whale Trades

Benzinga

Check Out What Whales Are Doing With JNJ

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 15 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's How Much You Would Have Made Owning Johnson & Johnson Stock In The Last 15 Years

Johnson & Johnson (NYSE:JNJ) has outperformed the market over the past 15 years by 1.01% on an annualized basis producing an average annual return of 7.22%. Currently, Johnson & Johnson has a market capitalization of $465.27 billion.

StockNews.com

2 Low-Beta Mega Stocks That Could Outperform the Market

The stock market has witnessed a free fall since the beginning of the year due to the Fed’s interest rate hikes and the recession fears. Moreover, interest rates are expected to rise further this year. Given the heightened volatility in the market, we think low beta mega stocks Johnson &…

Benzinga

What Are Whales Doing With Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 12 strange trades.

StockNews.com

Worried About A Market Meltdown? Then Buy These Stable Stocks Now

The rising inflation and the Fed’s aggressive rate hikes to clamp down on inflation are making investors anxious. Moreover, with analysts expecting multiple interest rate hikes in the coming months, recessionary fears are growing. As the market experiences a bout of volatility, fundamentally solid stocks Johnson & Johnson (JNJ), Roche…

Benzinga

Here's How Much You Would Have Made Owning Johnson & Johnson Stock In The Last 15 Years

Johnson & Johnson (NYSE:JNJ) has outperformed the market over the past 15 years by 1.05% on an annualized basis producing an average annual return of 7.34%. Currently, Johnson & Johnson has a market capitalization of $469.49 billion.

Benzinga

Check Out What Whales Are Doing With JNJ

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 20 strange trades.

StockNews.com

3 Dividend-Paying Healthcare Stocks to Outperform in the Bear Market

The bear market is creating a challenging environment for investors. One place to find outperformance could be high0-quality, healthcare stocks that are paying a dividend. Therefore, investors should consider dividend-paying healthcare stocks like Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Unitedhealth Group (UNH). .

1 … 11 12 13 14

People

Warren Buffett

2,115 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.